155 related articles for article (PubMed ID: 26578795)
1. Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis.
Phang BH; Othman R; Bougeard G; Chia RH; Frebourg T; Tang CL; Cheah PY; Sabapathy K
Proc Natl Acad Sci U S A; 2015 Nov; 112(46):E6349-58. PubMed ID: 26578795
[TBL] [Abstract][Full Text] [Related]
2. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations.
Delia D; Goi K; Mizutani S; Yamada T; Aiello A; Fontanella E; Lamorte G; Iwata S; Ishioka C; Krajewski S; Reed JC; Pierotti MA
Oncogene; 1997 May; 14(18):2137-47. PubMed ID: 9174049
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
Gu J; Kawai H; Wiederschain D; Yuan ZM
Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of NFkappaB-responsive gene expression by DeltaNp73alpha in p53 null cells.
Tanaka Y; Ota K; Kameoka M; Itaya A; Yoshihara K
Exp Cell Res; 2006 May; 312(8):1254-64. PubMed ID: 16430884
[TBL] [Abstract][Full Text] [Related]
5. p53 and disease: when the guardian angel fails.
Royds JA; Iacopetta B
Cell Death Differ; 2006 Jun; 13(6):1017-26. PubMed ID: 16557268
[TBL] [Abstract][Full Text] [Related]
6. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family.
Lomax ME; Barnes DM; Gilchrist R; Picksley SM; Varley JM; Camplejohn RS
Oncogene; 1997 Apr; 14(15):1869-74. PubMed ID: 9150393
[TBL] [Abstract][Full Text] [Related]
7. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
8. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation.
Goi K; Takagi M; Iwata S; Delia D; Asada M; Donghi R; Tsunematsu Y; Nakazawa S; Yamamoto H; Yokota J; Tamura K; Saeki Y; Utsunomiya J; Takahashi T; Ueda R; Ishioka C; Eguchi M; Kamata N; Mizutani S
Cancer Res; 1997 May; 57(10):1895-902. PubMed ID: 9157982
[TBL] [Abstract][Full Text] [Related]
9. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
10. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome.
Davison TS; Yin P; Nie E; Kay C; Arrowsmith CH
Oncogene; 1998 Aug; 17(5):651-6. PubMed ID: 9704931
[TBL] [Abstract][Full Text] [Related]
12. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
13. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
Olive KP; Tuveson DA; Ruhe ZC; Yin B; Willis NA; Bronson RT; Crowley D; Jacks T
Cell; 2004 Dec; 119(6):847-60. PubMed ID: 15607980
[TBL] [Abstract][Full Text] [Related]
15. Towards an understanding of the role of p53 in adrenocortical carcinogenesis.
Wasserman JD; Zambetti GP; Malkin D
Mol Cell Endocrinol; 2012 Mar; 351(1):101-10. PubMed ID: 21930187
[TBL] [Abstract][Full Text] [Related]
16. Genomic instability due to germline p53 mutations drives preneoplastic progression toward cancer in human cells.
Tainsky MA; Bischoff FZ; Strong LC
Cancer Metastasis Rev; 1995 Mar; 14(1):43-8. PubMed ID: 7606820
[TBL] [Abstract][Full Text] [Related]
17. Li-Fraumeni and Li-Fraumeni-like syndrome mutations in p53 are associated with exonic methylation and splicing regulatory elements.
Kouidou S; Malousi A; Maglaveras N
Mol Carcinog; 2009 Oct; 48(10):895-902. PubMed ID: 19367569
[TBL] [Abstract][Full Text] [Related]
18. A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53.
Glazer RI
Oncotarget; 2010 Nov; 1(7):470-471. PubMed ID: 21317445
[No Abstract] [Full Text] [Related]
19. Protein interaction between p53 and Δ113p53 is required for the anti-apoptotic function of Δ113p53.
Ou Z; Yin L; Chang C; Peng J; Chen J
J Genet Genomics; 2014 Feb; 41(2):53-62. PubMed ID: 24576456
[TBL] [Abstract][Full Text] [Related]
20. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
